Aug. 24 at 11:28 AM
$GH $167.14 bid. SELL/TAKE PROFIT on entire long position.
HISTORY:
DAC (dollar average cost includes partial SELLS to reduce investment cost to
$11.24 EXIT
$200.00
note: Originally, Legact Holding/ Major hoding took place on September 16, 2024 at
$23.00.
https://stocktwits.com/G101SPM/message/586148587
BRIEF: Guardant Health: TwinStrand Biosciences announces that the U.S. District Court for the District of Delaware entered final judgment in favor of the company and the University of Washington in their patent infringement suit against Guardant Health
TwinStrand Biosciences announces that the U.S. District Court for the District of Delaware entered final judgment on Aug. 21, 2026, in favor of TwinStrand and the University of Washington (UW) in their patent infringement suit against Guardant Health.
The final judgment preserves a November 2023 jury verdict finding that Guardant Health willfully infringed two core patents underlying TwinStrand's Duplex Sequencing technology across 11 royalty-bearing products and services, and awards TwinStrand and UW more than
$245.2 million in damages, accrued royalties and interest for infringement that occurred through May 31, 2026.
The judgment upholds the jury's
$83.4 million damages award for infringement through June 30, 2023, and follows the court's June 16, 2026, ruling resolving the parties' post-trial motions. The court awarded an additional
$19.5 million in supplemental damages for sales between July 1, 2023, and Feb. 5, 2024, and
$119.4 million in accrued royalties at a rate of 6% for sales between Feb. 5, 2024, and May 31, 2026.
The court also awarded
$22.9 million in pre-judgment and post-judgment interest. In determining past damages, the jury applied a 6% royalty to revenue attributed to the covered products and services, which represented approximately 90% of Guardant Health's total revenue during the relevant infringement period.
Going forward, the court ordered Guardant Health to pay this 6% royalty on sales of the covered products and services adjudicated at trial from June 1, 2026, through expiration of the patents on March 15, 2033, payable quarterly. Interest also continues to accrue on the unpaid judgment.
